
LISTING OF THE CLAIMS

1. (Previously presented) A modified fibronectin type III (Fn3) molecule comprising a stabilizing mutation of at least one residue involved in an unfavorable electrostatic interaction as compared to a wild-type Fn3, wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with another amino acid residue.
- 2-3. (Canceled)
4. (Previously presented) The Fn3 of claim 1, wherein Asp 7 or Asp 23, or both, have been substituted with an asparagine (Asn) or lysine (Lys) residue.
- 5-6. (Canceled)
7. (Previously presented) The Fn3 of claim 1, wherein Glu 9 has been substituted with an asparagine (Asn) or lysine (Lys) residue.
8. (Previously presented) The Fn3 of claim 1, wherein Asp 7, Asp 23, and Glu 9 have been substituted with at least one other amino acid residue.
- 9-53. (Canceled)
54. (Previously presented) The Fn3 of claim 1, wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with a neutral or positively charged amino acid residue.
55. (Previously presented) The Fn3 of claim 54, wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with a neutral amino acid residue.

56. (Previously presented) The Fn3 of claim 54, wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with a positively charged amino acid residue.
57. (Previously presented) A modified tenth type III module of fibronectin (FNfn10) molecule comprising a stabilizing mutation of at least one residue involved in an unfavorable electrostatic interaction as compared to a wild-type FNfn10 molecule, wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with another amino acid residue.
58. (Previously presented) The modified FNfn10 of claim 57, wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with a neutral or positively charged amino acid residue.
59. (Previously presented) The modified FNfn10 of claim 58, wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with a neutral amino acid residue.
60. (Previously presented) The modified FNfn10 of claim 58, wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with a positively charged amino acid residue.
61. (Previously presented) The modified FNfn10 of claim 58, wherein amino acid residues 7 or 23, or both, have been substituted with an asparagine (Asn) or lysine (Lys) residue.
62. (Previously presented) The modified FNfn10 of claim 58, wherein amino acid residue 9 has been substituted with an asparagine (Asn) or lysine (Lys) residue.

Applicant : Shohei Koide
Serial No. : 09/903,412
Filed : July 11, 2001
Page : 5 of 15

Attorney's Docket No.: 17027.003US1

63. (Previously presented) The modified FNfn10 of claim 57, wherein amino acid residues 7, 9 and 23 have been substituted with at least one other amino acid residue.